JP7475873B2 - ディフェンシン発現促進剤 - Google Patents
ディフェンシン発現促進剤 Download PDFInfo
- Publication number
- JP7475873B2 JP7475873B2 JP2020011294A JP2020011294A JP7475873B2 JP 7475873 B2 JP7475873 B2 JP 7475873B2 JP 2020011294 A JP2020011294 A JP 2020011294A JP 2020011294 A JP2020011294 A JP 2020011294A JP 7475873 B2 JP7475873 B2 JP 7475873B2
- Authority
- JP
- Japan
- Prior art keywords
- defensin
- present
- defensin expression
- expression
- expression promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000014509 gene expression Effects 0.000 title claims description 32
- 108010002069 Defensins Proteins 0.000 title claims description 27
- 102000000541 Defensins Human genes 0.000 title claims description 26
- 241000908178 Tremella fuciformis Species 0.000 claims description 18
- 150000004676 glycans Chemical class 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 8
- 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 claims description 6
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 102100038326 Beta-defensin 4A Human genes 0.000 claims description 4
- 102000055779 human DEFB103A Human genes 0.000 claims description 2
- 102000049262 human DEFB4A Human genes 0.000 claims description 2
- 210000001339 epidermal cell Anatomy 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 11
- 239000000284 extract Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 6
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 5
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 102000012265 beta-defensin Human genes 0.000 description 4
- 108050002883 beta-defensin Proteins 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 102100037437 Beta-defensin 1 Human genes 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000009414 Elaeocarpus kirtonii Nutrition 0.000 description 1
- 101150019065 HBD gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 244000236151 Tabebuia pallida Species 0.000 description 1
- 235000013584 Tabebuia pallida Nutrition 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 102000018568 alpha-Defensin Human genes 0.000 description 1
- 108050007802 alpha-defensin Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- -1 oral preparations Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
シロキクラゲ多糖体(Tremoist-TP、日本精化製)を0.1重量%の濃度で添加した培地(カルシウム濃度1.8mMに調整)にて、正常ヒト表皮角化細胞を24時間培養した後、細胞中のhBD-2及びhBD-3の遺伝子発現をリアルタイムPCR法により測定した。コントロールとしてシロキクラゲ多糖体が無添加の培地で培養した細胞における遺伝子発現量を同様に測定した。結果はコントロールの発現量を100%とした相対値として表1に示した。
Claims (2)
- シロキクラゲ多糖体を含有し、表皮細胞に作用させることを特徴とする、ヒトβ-ディフェンシン-2(hBD-2)又はヒトβ-ディフェンシン-3(hBD-3)発現促進剤。
- 請求項1に記載のディフェンシン発現促進剤を含有する、皮膚または生体内の抗菌作用を向上させるための組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020011294A JP7475873B2 (ja) | 2020-01-28 | 2020-01-28 | ディフェンシン発現促進剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020011294A JP7475873B2 (ja) | 2020-01-28 | 2020-01-28 | ディフェンシン発現促進剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021116267A JP2021116267A (ja) | 2021-08-10 |
JP7475873B2 true JP7475873B2 (ja) | 2024-04-30 |
Family
ID=77174013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020011294A Active JP7475873B2 (ja) | 2020-01-28 | 2020-01-28 | ディフェンシン発現促進剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7475873B2 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005306814A (ja) | 2004-04-23 | 2005-11-04 | Nippon Menaade Keshohin Kk | 皮膚外用剤 |
JP2012140336A (ja) | 2010-12-28 | 2012-07-26 | Rikomu:Kk | ヒトβディフェンシン2産生促進剤 |
-
2020
- 2020-01-28 JP JP2020011294A patent/JP7475873B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005306814A (ja) | 2004-04-23 | 2005-11-04 | Nippon Menaade Keshohin Kk | 皮膚外用剤 |
JP2012140336A (ja) | 2010-12-28 | 2012-07-26 | Rikomu:Kk | ヒトβディフェンシン2産生促進剤 |
Non-Patent Citations (4)
Title |
---|
GAO, Qipin et al.,Characterisation of acidic heteroglycans from Tremella fuciformisBerk with cytokine stimulating activity,Carbohydrate Research,1996年,Volume 288,Pages 135-142 |
富田哲治, 長瀬隆英,生体防御機構としてのディフェンシン,日本老年医学会雑誌,2001年,38巻 4号,p. 440-443 |
板東,美香,上皮細胞における抗菌ペプチドの発現調節機構の解明,四国歯学会雑誌,2011年,23 (2),p. 97-102 |
石井 (堤)裕子 等,殺菌ペプチドβ-defensinの発現制御,炎症・再生,21 巻 3号,2001年,p. 219-226 |
Also Published As
Publication number | Publication date |
---|---|
JP2021116267A (ja) | 2021-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090263339A1 (en) | Agent for external application to the skin | |
KR20070055372A (ko) | 구아바 발효 조성물 및 그 용도 | |
KR102149973B1 (ko) | 유제놀 및 갈릭산을 유효성분으로 함유하는 항균 및 항진균 조성물 | |
KR20180102431A (ko) | 푸코실락토오스를 포함하는 피부 노화 개선용 화장료 조성물 | |
JP2019529533A (ja) | 皮膚ケアおよび/または創傷治癒促進におけるポリ抽出物およびその有効成分の使用 | |
JP2023547872A (ja) | 新規なラクトバチルス属菌株及びその用途 | |
KR101225114B1 (ko) | 봉독을 유효성분으로 함유하는 피부 미백 및 피부질환 예방 및 치료용 조성물 | |
JP2009286746A (ja) | 冬虫夏草菌セミタケを含む外用剤 | |
KR101838404B1 (ko) | 올리고키토산을 유효성분으로 함유하는 여드름 예방 또는 치료용 조성물 | |
JP6162341B2 (ja) | 抗真菌ペプチドとテルペンアルコールとを含有する抗真菌組成物 | |
KR20190088286A (ko) | 아스페르길루스 크리스타투스 균주로 발효시킨 발효 콩의 추출물을 포함하는 피부미용 개선용 조성물 | |
JP7475873B2 (ja) | ディフェンシン発現促進剤 | |
KR101638664B1 (ko) | 5-아미노레불린산을 포함하는 피부감염증 예방 또는 치료용 약학 조성물 | |
JP6861134B2 (ja) | ヒアルロン酸産生促進剤及びヒアルロン酸産生促進用食品 | |
JP7153899B2 (ja) | 美白剤及び皮膚化粧料 | |
CN111135124A (zh) | 含有蔗糖、吲哚-3-乙酸以及玫瑰果提取物的混合物的皮肤外用剂组合物 | |
JP2007131579A (ja) | 生理活性組成物及びその製造方法 | |
US8486459B2 (en) | Bulbine frutescens extract | |
JP2009191019A (ja) | 皮膚若しくは毛髪用化粧料 | |
JP3501855B2 (ja) | ジャックフルーツ抽出物含有抗菌・防腐剤及び化粧料 | |
KR102652809B1 (ko) | 피부 상태 개선용 조성물 | |
JP2019052114A (ja) | コラーゲン産生促進剤及びコラーゲン産生促進用食品 | |
KR102270290B1 (ko) | 진주 복합추출물을 유효성분으로 포함하는 피부 개선용 조성물 | |
KR101436923B1 (ko) | 서시움 속 식물 추출물을 포함하는 항균용 구강 조성물 | |
KR102609656B1 (ko) | 스타필로코커스 호미니스 균주 및 그의 피부 상태 개선 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221205 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240122 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240409 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240417 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7475873 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |